What Happened?
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 2.9% in the morning session after Wolfe Research downgraded the stock to 'Underperform' from 'Peerperform', citing valuation concerns.
The firm set a price target of $50.00 per share. According to Wolfe Research, Corcept's current valuation already assumes a series of successful outcomes, including a successful Cushing's NDA resubmission, limited impact from generic competition, favorable legal decisions, and other pipeline wins. The downgrade suggests the analyst believes the stock's price already reflects these potential positives, leaving it vulnerable if these events do not materialize.
The shares were trading at $91.17, down 4.4% from the previous close.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Corcept? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Corcept’s shares are very volatile and have had 29 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 7 months ago when the stock dropped 51.4% on the news that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) rejecting the company's New Drug Application for relacorilant. The drug, which was being developed to treat hypertension in patients with hypercortisolism, failed to secure approval because the FDA concluded the submitted data was insufficient. Specifically, regulators noted they could not finalize a favorable benefit-risk assessment without additional evidence regarding the drug's effectiveness. This rejection blindsided investors who had widely expected approval based on earlier phase 3 trial results, triggering a massive sell-off as the market repriced the stock to exclude immediate revenue from this key pipeline asset.
The dramatic plunge underscores the high stakes surrounding Corcept's effort to diversify beyond Korlym. Relacorilant was viewed as a critical successor that would offer patients a safer, more selective treatment option with fewer side effects. By issuing the CRL, the FDA has effectively paused Corcept's growth narrative, raising fears that the company may need to conduct another costly and time-consuming clinical trial. Management stated they intend to request a meeting with the FDA immediately to clarify the deficiencies, but the uncertainty of the path forward has fundamentally shaken investor confidence in the company's near-term future.
Corcept is up 139% since the beginning of the year, and at $91.17 per share, it is trading close to its 52-week high of $96.66 from July 2026. Investors who bought $1,000 worth of Corcept’s shares 5 years ago would now be looking at an investment worth $4,554.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.